AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01033188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double bundle
Description: Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon.
Study NCT01527175 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Approach for ultrasound-guided subclavian venous catheterization
Description: Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
Study NCT01527175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Approach for ultrasound-guided subclavian venous catheterization
Description: Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
Study NCT04489459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
Study NCT04489459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
Study NCT04489459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
Study NCT03250871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
Study NCT03250871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
Study NCT02550041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: T specific response for diagnostic of aspergillus bronchitis
Study NCT04118842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
Study NCT04118842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
Study NCT03005418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
Study NCT01739361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT01739361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02398838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home administration of 200 mg mifepristone
Description: Home administration of 200 mg mifepristone.
Study NCT02398838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Home or clinic administration of 400 mcg buccal misoprostol
Description: Home or clinic administration of 400 mcg buccal misoprostol
Study NCT02398838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home or clinic administration of 400 mcg buccal misoprostol
Description: Home or clinic administration of 400 mcg buccal misoprostol
Study NCT03342079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics,Topical
Description: topical anesthetic
Study NCT04488939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Skinboosters™ Vital (SBV)
Description: Hyaluronic acid
Study NCT03342079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo topical anesthetic
Study NCT03342079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo topical anesthetic
Study NCT00932919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thought field therapy
Description: 5 sessions with Thought field therapy
Study NCT02502175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opium
Description: Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
Study NCT02502175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
Study NCT02002832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone tablets
Description: Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
Study NCT02002832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone tablets
Description: Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
Study NCT01356940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: identical placebo tablet administered bid for four weeks
Study NCT01356940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo tablet administered bid for four weeks
Study NCT00932919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive therapy
Description: 12 sessions of Cognitive therapy
Study NCT02926846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous vancomycin & gentamicin with adjunctive lavage
Description: Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Study NCT00932919 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list
Description: 3 months waiting, then randomized to either thought field therapy or cognitive therapy
Study NCT05475470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: finger-blade technique
Description: laparoscopic access technique for group a
Study NCT05475470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hasson's technique
Description: laparoscopic access technique for group b
Study NCT05475470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: veress needle technique
Description: laparoscopic access technique for group c
Study NCT04473261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idoine Complex
Description: Iodine Complex spray form 2 puffs will be given three times a day
Study NCT03234868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impression procedure
Description: Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
Study NCT03234868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impression procedure
Description: Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
Study NCT03234868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crown manufacturing procedures
Description: Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
Study NCT03234868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crown manufacturing procedures
Description: Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
Study NCT01167595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP uP Protocol
Description: Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
Study NCT03021304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
Study NCT03218956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement: Protein intake
Description: Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine.
Study NCT05798208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure measurement
Description: Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
Study NCT00672256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Description: Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
Study NCT00266097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
Study NCT00266097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
Study NCT00266097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
Study NCT00266097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 5040 cGy, every week, up to 6 weeks
Study NCT00266097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
Study NCT00266097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
Study NCT02926846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal vancomycin & gentamicin
Description: Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Study NCT01246518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOB015
Description: Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
Study NCT01123291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: follow-up coronary angiography
Description: follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
Study NCT01123291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical follow-up
Description: no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
Study NCT04378582 — intervention group
Intervention type: OTHER
Intervention: risk factors
Description: This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
Study NCT03962192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attitudinal measures
Description: A collection of 3 distinct attitudinal instruments comprise this survey.
Study NCT03422510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
Study NCT00611325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
Study NCT00611325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
Study NCT04053829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOLOBalance
Description: The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists.
Study NCT04053829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTAGO Home Exercise Programme
Description: The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
Study NCT03888820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Study NCT03888820 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Study NCT03379415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Footwear
Description: Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
Study NCT03379415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait analysis will be done during several different tasks wear the footwear
Study NCT01487564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 16 mg
Description: type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
Study NCT02560103 — intervention group
Intervention type: OTHER
Intervention: Transmeridian travel across multiple time zones
Study NCT04371718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122
Description: JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
Study NCT00964873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090 (ganetespib)
Description: Chemotherapy agent
Study NCT02192476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional neuro rehabilitation programme
Description: All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
Study NCT02192476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional neuro rehabilitation programme
Description: All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
Study NCT02192476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: California tri-pull taping (CTPT)
Description: Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape.
Study NCT01892189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.
Study NCT04371718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule has same component but active drug
Study NCT03136263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
Study NCT03136263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
Study NCT02893228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline
Description: At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
Study NCT02893228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
Study NCT02893228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia